Catalent’s OptiForm Solution Suite and OptiForm Solution Suite Bio platforms won the “Excellence in Pharma: Contract Services and Outsourcing” award at the annual CPhI Pharma Awards.

The OptiForm Solution Suite is an integrated service designed for early stage small molecules. It incorporates comprehensive molecule characterization and parallel evaluation of four formulation technologies, including salt form optimization, lipid formulation, solid dispersion and particle size reduction. OptiForm Solution Suite matches the best formulation technologies to each molecule, and uses an accelerated parallel screening and development protocol to provide in vivo study material in 12 weeks, including two weeks’ stability data.

To expand the service to the early phase development of peptides and macromolecules , OptiForm Solution Suite Bio was launched to rapidly screen biomolecules’ potential for non-invasive, oral delivery. It employs two formulation technologies, OptiGel Bio and Zydis Bio, and uses a parallel screening model to deliver in vivo study material within three weeks.

“We are delighted that the OptiForm Solution Suite platform has won further industry recognition, having won the ‘Editor’s Choice’ category at the annual Interphex awards earlier this year,” said Julien Meissonnier, vice president, science and technology, Catalent. “OptiForm Solution Suite offers easy, simple, fast and cost effective approaches for both small and macromolecules in early development phases. Our recent acquisition of Pharmatek will add their extensive early-phase drug development capabilities, and pharmaceutical spray dry expertise as a further option to overcome bioavailability issues.”